Literature DB >> 35716291

Differential response of hepatocellular carcinoma glycolytic metabolism and oxidative stress markers after exposure to human amniotic membrane proteins.

Andreia P Alves1,2, Sandra M Rocha1, Ana C Mamede1,2,3,4, Patrícia C Braga5, Marco G Alves5, Pedro F Oliveira6, Filomena M Botelho2,3,4, Cláudio J Maia7.   

Abstract

BACKGROUND: The human Amniotic Membrane (hAM) has been studied as a potential therapeutic option in cancer, namely in hepatocellular carcinoma. Previously, our research group evaluated the effect of human Amniotic Membrane Protein Extracts (hAMPE) in cancer therapy, demonstrating that hAMPE inhibit the metabolic activity of human hepatocellular carcinoma cell lines: Hep3B2.1-7, HepG2 and Huh7. Therefore, and considering the close relationship between metabolic activity and oxidative stress, the aim of this study was to evaluate the effect of hAMPE treatment in glucose metabolism and its role in oxidative stress of hepatocellular carcinoma. METHODS AND
RESULTS: Glucose uptake and lactate production was assessed by 1 H-NMR, and the expression of several mediators of the glycolytic pathway was evaluated by Western blot or fluorescence. Total antioxidant capacity (TAC) and biomarkers of oxidative stress effects in proteins were detected. Our results showed that hAMPE treatment increased glucose consumption on Hep3B2.1-7, HepG2, and Huh7 through the increase of GLUT1 in Hep3B2.1-7 and Huh7, and GLUT3 in HepG2 cells. It was observed an increased expression of 6-phosphofrutokinase (PFK-1L) in all cell lines though glucose was not converted to lactate on HepG2 and Huh7 cells, suggesting that hAMPE treatment may counteract the Warburg effect observed in carcinogenesis. In Hep3B2.1-7, hAMPE treatment induced an increase in expression of lactate dehydrogenase (LDH) and monocarboxylate transporter isoform 4 (MCT4). We further detected that hAMPE enhances the TAC of culture media after 2 and 8 h. This was followed by a degree of protection against proteins nitration and carbonylation.
CONCLUSIONS: Overall, this work highlights the potential usefulness of hAMPE as anticancer therapy through the modulation of the glycolytic and oxidative profile in human hepatocellular carcinoma.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Glycolysis; Hepatocellular carcinoma; Human amniotic membrane; Metabolism; Oxidative stress; Therapy

Mesh:

Substances:

Year:  2022        PMID: 35716291     DOI: 10.1007/s11033-022-07598-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  5 in total

1.  Hepatocellular carcinoma and chemotherapy: the role of p53.

Authors:  A F Brito; A M Abrantes; C Pinto-Costa; A R Gomes; A C Mamede; J Casalta-Lopes; A C Gonçalves; A B Sarmento-Ribeiro; J G Tralhão; M F Botelho
Journal:  Chemotherapy       Date:  2012-12-21       Impact factor: 2.544

Review 2.  Glucose Transporter Regulation in Cancer: A Profile and the Loops.

Authors:  Mutong Zhao; Zhenyu Zhang
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2016       Impact factor: 1.807

3.  Human amniotic membrane mesenchymal stem cell-conditioned medium reduces inflammatory factors and fibrosis in ovalbumin-induced asthma in mice.

Authors:  Fereshteh Dalouchi; Raza Falak; Morteza Bakhshesh; Zeynab Sharifiaghdam; Yaser Azizi; Nahid Aboutaleb
Journal:  Exp Physiol       Date:  2021-01-07       Impact factor: 2.969

Review 4.  Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside.

Authors:  Ming-Cheng Guan; Ming-Da Wang; Si-Yu Liu; Wei Ouyang; Lei Liang; Timothy M Pawlik; Qiu-Ran Xu; Dong-Sheng Huang; Feng Shen; Hong Zhu; Tian Yang
Journal:  World J Gastrointest Oncol       Date:  2021-04-15

5.  Prognostic value of glucose transporter 3 expression in hepatocellular carcinoma.

Authors:  Hengjun Gao; Yijie Hao; Xu Zhou; Hongguang Li; Fangfeng Liu; Huaqiang Zhu; Xie Song; Zheyu Niu; Qingqiang Ni; Min-Shan Chen; Jun Lu
Journal:  Oncol Lett       Date:  2019-12-09       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.